Decentralized Clinical Trial
DCT
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
A decentralized clinical trial conducts some or all trial activities at locations other than a traditional investigator site — the participant's home, a local provider, a pharmacy, or via telehealth and connected devices. DCT elements can be applied fully or in a hybrid model and are intended to reduce participant burden and broaden access, while preserving the same GCP obligations for consent, safety oversight, data integrity, and investigator responsibility. The shift changes logistics, not the standards.
Decentralization raises specific control questions: how investigational product is shipped and accounted for, how remote personnel are delegated and trained, how e-source and connected-device data preserve ALCOA+ attributes, and how safety events are captured and escalated outside a clinic.
Regulators have issued dedicated guidance treating DCTs as a design choice within existing GCP, not a separate regulatory regime — the trial master file must still evidence oversight of every decentralized activity.
- —Full or hybrid; activities move to home, local provider, or telehealth
- —Same GCP duties for consent, safety, data integrity, investigator oversight
- —Product accountability and remote delegation are the hard control points
- —e-source and device data must still satisfy ALCOA+
FDA guidance on decentralized clinical trials; EMA/HMA recommendation paper on decentralised elements in clinical trials; ICH E6(R3).
Frequently asked questions
What does Decentralized Clinical Trial stand for?
Decentralized Clinical Trial stands for DCT.
What is Decentralized Clinical Trial?
A decentralized clinical trial conducts some or all trial activities at locations other than a traditional investigator site — the participant's home, a local provider, a pharmacy, or via telehealth and connected devices. DCT elements can be applied fully or in a hybrid model and are intended to reduce participant burden and broaden access, while preserving the same GCP obligations for consent, safety oversight, data integrity, and investigator responsibility. The shift changes logistics, not the standards.
Which regulations cover Decentralized Clinical Trial?
FDA guidance on decentralized clinical trials; EMA/HMA recommendation paper on decentralised elements in clinical trials; ICH E6(R3).